A carregar...
Cost-effectiveness analysis and budget impact of rivaroxaban compared with dalteparin in patients with cancer at risk of recurrent venous thromboembolism
OBJECTIVES: In the ‘Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism’ (SELECT-D) trial, rivaroxaban showed relatively low venous thromboembolism (VTE) recurrence but higher bleeding compared with dalteparin in patients wi...
Na minha lista:
| Publicado no: | BMJ Open |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMJ Publishing Group
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7678368/ https://ncbi.nlm.nih.gov/pubmed/33444193 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2020-039057 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|